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Abstract
Background
Socio-economic, cultural and environmental factors are becoming increasingly important
determinants of chronic obstructive pulmonary disease (COPD). We conducted a study to
investigate socio-demographic, lifestyle and clinical factors, and to assess their role as pre-
dictors of acute events (mortality or hospitalization for respiratory causes) in a group of
COPD patients.
Methods
Subjects were recruited among outpatients who were undertaking respiratory function tests
at the Pneumology Unit of the Sant’Orsola-Malpighi Hospital, Bologna. Patients were classi-
fied according to the GOLD Guidelines.
Results
229 patients with COPD were included in the study, 44 with Mild, 68 Moderate, 52 Severe
and 65 Very Severe COPD (GOLD stage). Significant differences among COPD stage, in
terms of smoking status and fragility index, were detected. COPD stage significantly
affected the values of all clinical tests (spirometry and ABG analysis). Kaplan-Meier esti-
mates showed a significant difference between survival curves by COPD stage with lower
event-free probability in very severe COPD stage. Significant risk factors for acute events
were: underweight (HR = 4.08; 95% CI 1.01–16.54), having two or more comorbidities (HR
= 4.71; 95% CI 2.52–8.83), belonging to moderate (HR = 3.50; 95% CI 1.01–12.18) or very
severe COPD stage (HR = 8.23; 95% CI 2.35–28.85).
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Conclusions
Our findings indicate that fragility is associated with COPD stage and that comorbidities and
the low body mass index are predictors of mortality or hospitalization. Besides spirometric
analyses, FeNOmeasure and comorbidities, body mass index could also be considered in
the management and monitoring of COPD patients.
Introduction
Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by persis-
tent airflow limitation, usually progressive, associated with enhanced chronic inflammatory
response in the airways and the lung to noxious particles or gases [1]. COPD is a leading cause
of morbidity and mortality worldwide, with peaks in particular in low and middle-income
countries, and is responsible for an increase in social costs by governments and individuals.
The Global Burden of Disease Study estimated that COPD will become the third leading
cause of death worldwide by 2020 [2]. In addition, considering the sum of years lost because of
premature mortality and years of life lived with disability [Disability-Adjusted Life Year
(DALY)], it has been estimated that by 2030 COPD will be the seventh leading cause of DALYs
lost worldwide [2]. In Italy, COPD affects about 14% of the older population (65 years or
more) and is the fifth cause of hospital admission in this age group. Several variables have been
identified as factors influencing COPD life expectancy, including smoking, degree of dyspnoea,
age, exercise capacity, body mass index (BMI), exacerbations, comorbidities, and quality of life
[3–10]. They may be valuable in the assessment of severity and progression of disease and eval-
uate the response to medical intervention [11–12]. Several prognostic COPD indices have been
identified [12]. However applying a prognostic index in a patient population other than the
one in which it was developed, may require recalibration and/or modification [12].
At the base of major chronic diseases, such as COPD, there are common and modifiable
risk factors, including unhealthy diet, tobacco use, alcohol abuse, and lack of physical activity
but also non-modifiable risk factors such as age and genetic predisposition. In the last years,
socio-economic, cultural, political and environmental factors are becoming increasingly
important determinants of COPD. In view of this, we conducted a study to investigate socio-
demographic, lifestyle and clinical factors in a population affected by COPD, and to assess
their role as predictors of acute events (mortality or hospitalization for respiratory causes) in a
group of COPD patients.
Materials and Methods
Subjects
The study was conducted as part of the multidisciplinary project Respirare Bologna (Breath
Bologna) aimed at assessing determinants of health status outcomes in COPD patients.
Subjects were enrolled consecutively among outpatients who were undertaking respiratory
function tests at the Pneumology Unit of the Sant’Orsola-Malpighi Hospital, Bologna, from
October 2010 to July 2012. The only inclusion criterion was to be resident in Bologna, a city
located in Northern Italy of about 380,000 inhabitants. The Pneumology Unit is the centre
with the highest number of consultations within the four referral centres of the city, providing
respiratory functions tests. Patients are usually sent by the General Practitioners for a first diag-
nosis of COPD and subsequent checks. COPD patients were classified according to GOLD
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guidelines [1] in: Mild (GOLD 1), Moderate (GOLD 2), Severe (GOLD 3) and Very Severe
(GOLD 4).
Ethics Statement
The present is an observational study where no new diagnostic tool and/or drug treatment was
provided to any participant. Participants were treated according to routine clinical care. Like-
wise, patients data were collected as part of standard clinical care during a routine consultation.
The authors were not involved in the patients medical treatment. According to the Italian law
on retrospective evaluation of case series (Gazzetta Ufficiale n. 76, 31-3-2008) ethics approval
was not necessary and authors did not ask for it. Nevertheless the study was conducted in
accordance to the Italian Law n. 196/2003 about personal data treatment (D. Lgs 30 giugno
2003, n. 196. Gazzetta Ufficiale 2003, 174, S.O., 2003). Data were anonymized prior to the anal-
yses after database linkage was done. Only one author conducting database linkage had access
to patients identifying information. Only patients who provided written informed consent
prior to participating in the study were enrolled according to the Helsinki Declaration and
later Amendments. No minors/children were enrolled in the present study.
Socio-demographic and clinical variables
Comprehensive socio-demographic, lifestyle and clinical data were collected by physician
interviewers through the use of a predefined questionnaire during a routine clinical consulta-
tion. In particular, as far as socio-demographic and lifestyle characteristics, the following infor-
mation were collected: age, gender, educational status, smoking status, including n. packs of
cigarettes/year and physical activity (having carried out any physical activity that caused an
increase in breathing, heart pulses or sweating). Moreover, for each participant a deprivation
and a fragility index were attributed.
The deprivation index was developed by Caranci et al. using variables from the 2001 Gen-
eral Census of Population and Housing [13]. Five traits that represented the multidimensional-
ity of the social and material deprivation concept were considered: low level of education,
unemployment, non-home ownership, one-parent family and household overcrowding. The
index is calculated by summing standardized indicators [13]. The fragility index, developed by
the Local Health Authority of Bologna represents the probability of acute hospitalization or
death in the following year and ranges from 0 to 100. The index was derived from a predictive
model following the experience of the Combined Predictive Model [14] which aims to identify
individuals at high-risk of re-hospitalization or death. The predictive model included demo-
graphic variables (age, gender), clinical variables such as heart failure, diabetes, cancer, lung
disease, hospitalizations and access to emergency care during the previous year and social vari-
ables (deprivation index).
The following clinical characteristics were collected for each participant: Charlson index,
Fraction Exhaled Nitric Oxide (FeNO), PaO2, PaCO2, pH, FVC, FEV1, FEV1/FVC (%), FVC
(% of total) and FEV1 (% of total). The Charlson Comorbidity Index contains 19 categories of
comorbidity [15]. In this paper this index is expressed in 3 categories: no comorbidity, one
comorbidity and two or more comorbidities. FeNO levels were evaluated using a Niox chemi-
luminescence analyser (Aerocrine AB, Solna, Sweden). According to the American Thoracic
Society (ATS) guideline, the subjects inhaled nitric oxide free air to total lung capacity and then
exhaled at a constant flow rate against a valve connected to the nitric oxide analyzer [16]. We
used the mean value of FeNO levels obtained in two tests. The measurements of pH, PaO2 and
PaCO2 were evaluated using arterial blood gas (ABG) analysis. FEV1 and FVC were obtained
by spirometry (Model N 403; Monaghan, Littleton, CO), with the spirometer calibrated daily.
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In addition, two anthropometric characteristics were collected: BMI and waist circumference.
BMI was determined from height and weight measured at the time of the first visit, and catego-
rized into four groups: underweight (<18.5kg/m2), normal (18.5–24.9kg/m2), overweight (25–
29.9 kg/m2) and obese (>30kg/m2).
Outcome
Acute events were defined in case of death for respiratory causes (X International Classification
of Diseases codes J00-J99) or hospitalization for respiratory causes (IX International Classifica-
tion of Diseases codes 460–519.9) occurred from October 2010 to December 2012 in and out-
side Bologna. Data were extracted from the Mortality Registry and the Hospital Admission
Database of the Local Health Authority of Bologna.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD), while categorical vari-
ables as absolute frequency (relative frequency). Kruskal-Wallis, Pearson’s chi-square and Fish-
er’s exact tests were used to compare variables among COPD GOLD stages as appropriate. The
unit of analysis was the patient. The survival function was calculated with Kaplan-Meier esti-
mates for each GOLD stage and compared using log-rank test. Univariate and multivariate
Cox regression analyses were performed to study the association between acute events and the
following risk factors: age, gender, BMI, educational qualification, physical activity, smoking
status, deprivation index, Charlson index and GOLD stages (Model 1). In a second model we
replicated the analyses omitting the GOLD stage (Model 2). In a sensitivity analyses clinical
variables such as PaO2 and FEV1 were considered instead of the GOLD stage. All P-values are
based on 2-sided tests and P 0.05 were considered significant. Statistical analysis was per-
formed using statistical package Stata Intercooled for Windows, version 12.0.
Results
Table 1 shows the results regarding the social and lifestyles characteristics observed in the
study population. 229 patients (129 male and 100 female; mean age 75±9.6 years) affected by
COPD were enrolled in the study. According to the GOLD Guideline patients were classified
as follows: 44 mild COPD, 68 moderate COPD, 52 severe COPD and 65 very severe COPD. In
the overall population 42% of the patients had an education level of primary school, the major-
ity (77.5%) did not practice any physical activity, more than 60% were ex-smokers and more
than 50% turned out to be deprived or very deprived. The mean fragility index was 26.1. Signif-
icant differences within COPD stage, in terms of smoking status, were detected. Interestingly, a
relationship between the increase of the fragility index and the severity of COPD was observed.
Table 2 provides the details of clinical and anthropometric characteristics of the study popu-
lation. There were non-significant differences in BMI and waist circumference among COPD
stage. On the contrary, the stage was significantly associated with the values of all clinical tests
(spirometry and ABG analysis). Furthermore the highest percentage of patients (42.2%) who
had two or more comorbidities was observed in the group suffering from very severe COPD.
During the study period 71 patients experienced at least one acute event (69 hospitalizations
and 14 deaths). Kaplan-Meier estimates show that there is a significant difference between sur-
vival curves by COPD stage (P< 0.001) (Fig 1).
In particular, by considering the single curves, patients in the mild group have a higher
event-free probability than patients in the moderate group (P = 0.024), patients in the severe
have a higher event-free probability than in the very severe group (P = 0.011) whereas in the
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moderate group patients do not show a significant difference in event-free probability com-
pared with the severe group (P = 0.93).
Characteristics significantly associated with acute events in the univariate analyses were the
Charlson index, COPD stage (Table 3) and FEV1(data not shown). In model 1, two or more
comorbidities and COPD stage (mild and very severe) were confirmed as risk factors. Two or
more comorbidities were associated with a 4.5-fold increased risk (HR = 4.50; 95% CI 2.39–
8.49; P< 0.001); moderate and very severe COPD stages were associated with a 3.5 and a 8.23
–fold increased risk for acute events (HR = 3.50; 95% CI 1.01–12.18, P = 0.049 and HR = 8.23;
95% CI 2.35–28.85, P = 0.0010 respectively). As the GOLD stage could be on the causal path-
way between some prognostic variables and COPD health status outcomes [17], we performed
a multivariate analysis omitting GOLD stage as a covariate (Model 2). In this analysis under-
weight was a risk factors for acute events (HR = 4.08; 95% CI 1.01–16.54; P = 0.049). In the sen-
sitivity analyses, when we included FEV1 and PaO2 instead of COPD stage in the model,
gender, the Charlson index and FEV1 proved to be associated with acute events. A greater risk
is observed in male gender vs female (HR 2.01; 95% CI 1.05–3.84), in patients with two or
more comorbidities versus patients without comorbidities (HR = 4.17; 95% CI 2.16–8.04). A
reduced risk is observed for every increase in 1 litre FEV1 (HR = 0.26; 95% CI 0.13–0.54) (S1
Table).
Table 1. Social and lifestyles characteristics in COPD population.
COPD GOLD STAGE
Mild Moderate Severe Very severe Total P-value
N° subjects 44 68 52 65 229
Age, mean±sd 74.9±9.2 75.3±12.0 74.1±7.9 75.3±8.3 75.0±9.6 0.52
Gender
Women 23 (52.3%) 32 (47.1%) 20 (38.5%) 25 (38.5%) 100 (43.7%)
Men 21 (47.7%) 36 (52.9%) 32 (61.5%) 40 (61.5%) 129 (56.3%) 0.40
Educational qualiﬁcation
Middle school 10 (23.3%) 20 (29.4%) 13 (25.0%) 14 (22.2%) 57 (25.3%)
No qualiﬁcation 5 (11.6%) 3 (4.4%) 3 (5.8%) 6 (9.5%) 17 (7.5%)
Primary school 16 (37.2%) 29 (42.7%) 20 (38.5%) 30 (47.6%) 95 (42.0%)
Diploma 7 (16.3%) 10 (14.7%) 12 (23.1%) 9 (14.3%) 38 (16.8%)
Degree 5 (11.6%) 6 (8.8%) 4 (7.7%) 4 (6.4%) 19 (8.4%) 0.89
Physical activity
No 29 (72.5%) 49 (72.1%) 45 (86.5%) 46 (79.3%) 169 (77.5%)
Yes 11 (27.5%) 19 (27.9%) 7 (13.5%) 12 (20.7%) 49 (22.5%) 0.23
Smoking status
Never-smoker 15 (34.1%) 22 (32.4%) 7 (13.5%) 6 (9.4%) 50 (21.9%)
Smoker 9 (20.5%) 7 (10.3%) 8 (15.4%) 8 (12.5%) 32 (14.0%)
Ex-smoker 20 (45.4%) 39 (57.3%) 37 (71.2%) 50 (78.1%) 146 (64.1%) 0.0030
Mean n. packs of cigarettes/year in smokers±sd 28.1±15.5 45.1±79.2 40.1±23.3 44.1±19.8 40.7±43.7 0.0033
Deprivation index
Very rich 9 (22.0%) 11 (16.9%) 9 (18.0%) 9 (14.8%) 38 (17.5%)
Rich 8 (19.5%) 8 (12.3%) 4 (8.0%) 6 (9.8%) 26 (12.0%)
Medium 3 (7.3%) 12 (18.5%) 10 (20.0%) 11 (18.0%) 36 (16.6%)
Deprived 9 (21.9%) 13 (20.0%) 10 (20.0%) 9 (14.8%) 41 (18.9%)
Very deprived 12 (29.3%) 21 (32.3%) 17 (34.0%) 26 (42.6%) 76 (35.0%) 0.73
Fragility, mean±sd 18.1±16.8 26.6±20.5 23.3±20.3 33.3±24.3 26.1±21.5 0.0024
doi:10.1371/journal.pone.0135116.t001
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Discussion
In this study we investigated a panel of socio-demographic and clinical factors in a population
affected by COPD, resident in Bologna. The overall study population consisted mostly of men,
ex-smokers, not practicing any physical activity, obese or overweight. With regard to the depri-
vation index, the majority of patients were deprived or very deprived, regardless of COPD
stage. Our findings are in line with previous literature’s results showing that smoking, aging,
Table 2. Clinical and anthropometric characteristics in COPD population.
COPD GOLD STAGE
Mild Moderate Severe Very severe Total P-value
BMI
Underweight 2 (4.6%) 0 (0.0) 3 (5.8%) 3 (4.7%) 8 (3.5%)
Normal 17 (38.6%) 16 (23.9%) 17 (32.7%) 25 (39.1%) 75 (33.0%)
Overweight 17 (38.6%) 32 (47.8%) 21 (40.4%) 22 (34.3%) 92 (40.5%)
Obese 8 (18.2%) 19 (28.3%) 11 (21.1%) 14 (21.9%) 52 (22.9%) 0.34
Waist circumference (cm) 96.4±12.5 101.6±12.3 101.0±14.6 100.1±15.0 100.0±13.7 0.39
Charlson index
No comorbidity 32 (72.7%) 33 (49.2%) 24 (46.2%) 20 (31.2%) 109 (48.0 &)
One comorbidity 3 (6.8%) 16 (23.9%) 9 (17.3%) 17 (26.6%) 45 (19.8%)
Two or more comorbidities 9 (20.5%) 18 (26.9%) 19 (36.5%) 27 (42.2%) 73 (32.2%) 0.0030
FeNO (ppb) 16.7±5.9 19.5±6.7 20.1±7.2 27.0±10.3 21.1±8.6 <0.001
PaO2 (mmHg) 79.7±8.9 73.8±10.0 69.9±10.1 71.1±14.8 73.1±12.2 <0.001
PaCO2 (mmHg) 38.3±4.1 40.4±5.6 41.8±6.9 49.7±10.5 43.0±8.7 <0.001
pH 7.44±0.03 7.43±0.03 7.44±0.08 7.42±0.04 7.43±0.05 0.048
FVC (L) 2.8±0.8 2.2±0.8 2.0±0.6 1.6±0.6 2.2±0.8 <0.001
FEV1 (L) 1.9±0.6 1.3±0.4 1.0±0.3 0.7±0.3 1.2±0.6 <0.001
FEV1/FVC (%) 67.6±6.6 59.9±11.1 51.9±12.9 45.5±11.8 55.6±13.6 <0.001
FVC (% of total) 102.9±19.5 81.3±14.5 69.6±16.3 57.1±17.8 76.0±23.2 <0.001
FEV1 (% of total) 87.8±13.5 61.4±7.5 44.8±9.6 32.8±12.2 54.7±22.3 <0.001
doi:10.1371/journal.pone.0135116.t002
Fig 1. Kaplan-Meier analyses show that there is a significant difference between survival curves by
COPD stage. The very severe COPD group has a lower event-free probability than subjects in the other
stages. The mild COPD group has the highest event-free probability.
doi:10.1371/journal.pone.0135116.g001
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gender, and socio-economic factors are well established risk factors for COPD development
[18]. Interestingly, taking into account the COPD GOLD stage, we observed a significant asso-
ciation between the fragility value, smoking status and the severity of the disease. Moreover we
noted the highest percentage of patients with two or more comorbidities in patients suffering
from very severe COPD. According to the literature, FeNO values are normal or mildly
Table 3. Cox proportional hazardsmodel of COPD population.
Model 1 Model 2
Event HR unadjusted (95% CI) P-value HR adjusteda (95% CI) P-value HR adjustedb (95% CI) P-value
Age, mean±sd 76.33 ±8.48 1.02 (0.99–1.05) 0.25 1.00 (0.96–1.03) 0.80 1.00 (0.97–1.04) 0.88
Gender
Women 29 (40.9%) 1.00 1.00 1.00
Men 42 (59.2%) 1.19 (0.74–1.91) 0.48 1.33 (0.73–2.42) 0.35 1.27 (0.71–2.25) 0.42
BMI
Normal 22 (31.4%) 1.00 1.00 1.00
Underweight 3 (4.3%) 1.88 (0.56–6.31) 0.31 3.20 (0.73–14.11) 0.12 4.08 (1.01–16.54) 0.049
Overweight 29 (41.4%) 1.09 (0.62–1.89) 0.77 1.25 (0.66–2.36) 0.49 1.25 (0.67–2.34) 0.49
Obese 16 (22.9%) 1.01 (0.53–1.93) 0.96 0.87 (0.42–1.80) 0.71 0.87 (0.42–1.80) 0.70
Educational qualiﬁcation
Middle school 16 (22.9%) 1.00 1.00 1.00
No qualiﬁcation 6 (8.6%) 1.27 (0.50–3.24) 0.62 1.15 (0.40–3.32) 0.80 1.24 (0.46–3.39) 0.67
Primary school 31 (44.3%) 1.26 (0.69–2.31) 0.45 0.97 (0.50–1.88) 0.92 1.03 (0.53–2.03) 0.92
Diploma 10 (14.3%) 0.95 (0.43–2.09) 0.89 1.04 (0.44–2.45) 0.94 1.10 (0.48–2.51) 0.83
Degree 7 (10.0%) 1.26 (0.52–3.07) 0.61 1.41 (0.51–3.91) 0.51 1.32 (0.47–3.68) 0.60
Physical activity
No 56 81.2%) 1.00 1.00 1.00
Yes 13 (18.8%) 1.04 (0.56–1.91) 0.90 1.28 (0.62–2.62) 0.51 1.50 (0.73–3.07) 0.27
Smoking status
Never-smoker 13 (18.3%) 1.00 1.00 1.00
Smoker 8 (11.3%) 0.98 (0.40–2.36) 0.96 0.83 (0.28–2.41) 0.73 1.12 (0.39–3.23) 0.83
Ex-smoker 50 (70.4%) 1.48 (0.80–2.72) 0.21 0.94 (0.43–2.08) 0.89 1.39 (0.66–2.93) 0.39
Charlson index
No comorbidity 17 (24.3%) 1.00 1.00 1.00
One comorbidity 12 (17.1%) 1.76 (0.84–3.70) 0.13 1.27 (0.55–2.89) 0.58 1.74 (0.78–3.93) 0.18
Two or more comorbidities 41 (58.6%) 4.44 (2.52–7.82) <0.001 4.50 (2.39–8.49) <0.001 4.71 (2.52–8.83) <0.001
Deprivation index
Very rich 13 (19.1%) 1.00 1.00 1.00
Rich 5 (7.4%) 0.50 (0.18–1.40) 0.19 0.51 (0.14–1.84) 0.31 0.49 (0.15–1.63) 0.25
Medium 11 (16.2%) 0.83 (0.37–1.85) 0.65 1.02(0.35–2.95) 0.97 1.35 (0.51–3.54) 0.55
Deprived 11 (16.2%) 0.65 (0.29–1.46) 0.30 0.72 (0.27–1.93) 0.51 0.89 (0.35–2.25) 0.80
Very deprived 28 (41.2%) 1.06 (0.55–2.05) 0.86 0.98 (0.36–2.67) 0.97 1.28 (0.52–3.14) 0.59
COPD stage
Mild 4 (5.6%) 1.00 1.00 -
Moderate 19 (26.8%) 3.21 (1.09–9.44) 0.034 3.50 (1.01–12.18) 0.049 -
Severe 15 (21.1%) 3.22 (1.07–9.70) 0.038 2.87 (0.78–10.54) 0.11 -
Very severe 33 (46.5%) 7.37 (2.61–20.82) <0.001 8.23 (2.35–28.85) 0.0010 -
aHR adjusted for age, gender, BMI, educational qualiﬁcation, physical activity, smoking status, Charlson index, deprivation index and COPD stage
bHR adjusted for age, gender, BMI, educational qualiﬁcation, physical activity, smoking status, Charlson index and deprivation index
doi:10.1371/journal.pone.0135116.t003
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increased in stable COPD [19] and measurement of FeNO represents a non-invasive marker
that may be useful to detect exacerbations and inflammation reduction in small airway disease
[20]. In our study population FeNO values are associated with the severity of COPD. Given the
type of study, we cannot deduce the direction of the association: frail subjects evolve more rap-
idly to very severe COPD stage but on reverse, COPD stage could increase the fragility of the
patients.
Another objective of the present study was to identify predictors of acute events in terms of
death or hospitalization in COPD patients. During the study period 71 patients had at last one
acute event. Our findings indicate that subjects with very severe COPD or low FEV1 are at
higher risk of death or hospitalization for respiratory causes compared to patients with mild
COPD, confirming the validity of the spirometric test as prognostic factor. Our data confirm
that patients classification according to the GOLD spirometric grading systems represents a
predictor of exacerbations, hospitalizations and death [21–22].
COPD often coexists with other diseases and the scientific literature highlights that they
may significantly impact on prognosis [1]. Our analyses confirms that the Charlson index is a
risk factor for acute events, strengthening its role in COPD diagnosis and prognosis of poor
outcomes. In addition, some studies highlighted a role of low BMI as an important risk factor
for acute events, in particular showing that underweight and low skeletal muscle mass are sig-
nificant determinants of mortality in COPD [23–27]. Our multivariate analysis provides results
in line with the literature suggesting that recording of weight should be part of the follow up of
these patients. The heterogeneous distribution of underweight among patients with different
characteristics (e.g. deprivation) and the sample size may explain the non significant results of
BMI as a risk factor in the bivariate analyses.
Previous studies have examined the association between socio-economic status and COPD
health outcomes but results are controversial, possibly due to the different accessibility to
health care [28–31]. Eisner et al. [17] found that socio-economic status represents a risk factor
for adverse COPD health outcomes; in contrast, in our study the deprivation index does not
influence the incidence of acute events. Differences between the US and the Italian health care
system could explain the different results between the two studies. In particular, the access to
the national health service guaranteed to the entire population might mitigate the effect of
deprivation.
Our study measured only respiratory-associated events. Deaths in individuals with COPD
are frequently attributed to a cause other than respiratory such as cardiovascular disease or
other causes [18]. Our results are therefore not directly generalizable to events for other
causes. Indeed, this could represent a limitation of our study, however the main aim has been
to assess the efficacy of a panel of life-style and clinical factors as predictors of acute events,
including mortality and/or hospitalization, for respiratory causes. Another limitation is the
small sample size, consequently we cannot exclude that predictors investigated in the present
study might result significantly associated with the outcomes under investigation in larger
studies.
In conclusion, a relationship between the increase of the fragility index and the severity of
COPD was observed. Moreover, our findings indicate that the Charlson index is associated
with disease evolution and that it could be considered as a risk factor for acute events. On the
other hand, the deprivation index does not influence both disease evolution and acute events,
probably because the accessibility to the Italian National Health Service, countervails the effects
associated to socio-economic status. Furthermore, besides spirometric analyses and FeNO
measure, our findings suggest that BMI could be considered in the management and monitor-
ing of COPD patients.
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